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Effect of fish oil supplementation in pregnancy on bone, lean, 
and fat mass at six years: randomised clinical trial 
Rebecca Kofod Vinding,1,2 Jakob Stokholm,1 Astrid Sevelsted,1 Tobias Sejersen,1, 2  
Bo L Chawes,1 Klaus Bønnelykke,1 Jonathan Thorsen,1 Laura D Howe,3 Martin Krakauer,4  
Hans Bisgaard1
ABSTRACT
OBJECTIVE
To examine the effect of supplementation with n-3 
long chain polyunsaturated fatty acids (n-3 LCPUFA) 
in pregnancy on anthropometry and body composition 
in offspring.
DESIGN
Double blinded, randomised controlled trial.
SETTING
Copenhagen Prospective Studies on Asthma in 
Childhood2010 cohort.
PARTICIPANTS
736 pregnant women and their offspring.
INTERVENTION
n-3 LCPUFA (fish oil) or control (olive oil) daily from 
pregnancy week 24 until one week after birth.
MAIN OUTCOME MEASURES
Height/length, weight, head, and waist measurements 
and body composition from dual energy x ray 
absorptiometry (all pre-specified secondary endpoints 
of the n-3 LCPUFA trial; the primary outcome for the 
trial was persistent wheeze/asthma).
RESULTS
The mean body mass index (BMI) z score was 
increased between age 0 and 6 years in the fish oil 
supplementation group compared with the control 
group (0.14 (95% confidence interval 0.04 to 0.23); 
P=0.006). At 6 years, supplementation was associated 
with a higher BMI z score (0.19 (0.06 to 0.32); 
P=0.004), a higher weight/height (3.48 (0.38 to 6.57) 
g/cm; P=0.03), and a larger waist circumference (0.6 
(0.0 to 1.2) cm; P=0.04) but not a higher proportion of 
obese children, using International Obesity Task Force 
grades. The dual energy x ray absorptiometry scan at 
age 6 years showed a higher total mass (395.4 (86.6 to 
704.3) g; P=0.01) in the supplementation versus the 
control group, explained by a higher lean mass (280.7 
(98.9 to 462.4) g; P=0.002), a higher bone mineral 
content (10.3 (2.3 to 18.1) g; P=0.01), and a non-
significantly higher fat mass (116.3 (−92.9 to 325.5) g; 
P=0.28), but no differences were seen in total body fat 
or lean mass percentage.
CONCLUSION
Fish oil supplementation from the 24th week of 
pregnancy led to a higher BMI in the offspring from 0 
to 6 years of age but not an increased risk of obesity at 
age 6. The body composition at age 6 years in children 
given fish oil supplementation was characterised by 
a proportional increase in lean, bone, and fat mass 
suggesting a general growth stimulating effect of n-3 
LCPUFA.
TRIAL REGISTRATION
Clinicaltrials.gov NCT00798226
Introduction
Diet during pregnancy and infancy is an important 
determinant for children’s development and health.1 
In particular, intake of fish containing n-3 long chain 
polyunsaturated fatty acids (LCPUFA) is important 
for adequate development.2 In humans, both 
observational studies on dietary intake of fish and 
randomised controlled trials of n-3 LCPUFA (fish oil) 
supplementation in pregnancy and during lactation 
have consistently shown higher birth weight in children 
born to women with higher n-3 LCPUFA intake; this 
is mainly explained by an increase in gestational 
age, but an increase in size for gestational age has 
not been excluded.3-6 However, the long term effect 
on anthropometry during childhood is uncertain.7-10 
Mechanistic studies in rats have shown that n-3 
LCPUFA supplementation both during pregnancy and 
in the postnatal period affects the proliferation and 
differentiation of pre-adipocytes, which theoretically 
could prevent adiposity through inhibition of fat 
tissue.11  12 Despite these possible mechanisms, a 
recent systematic review of animal studies concluded 
that the evidence was insufficient to draw any definite 
conclusions on the role of n-3 LCPUFA supplied during 
pregnancy, lactation, or both on fat mass development 
in the offspring.13
Randomised controlled trials with n-3 LCPUFA 
supplementation in pregnancy and/or during lactation 
have shown diverging results but mainly no effects 
on anthropometric outcomes. Recent reviews have 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Animal studies have shown that n-3 long chain polyunsaturated fatty acids  
(n-3 LCPUFA) supplementation both during pregnancy and in the postnatal  
period affects adipogenesis
However, in humans, randomised trials with n-3 LCPUFA supplementation in 
pregnancy have shown ambiguous results regarding anthropometric outcomes 
later in childhood
WHAT THIS STUDY ADDS
n-3 LCPUFA supplementation in pregnancy led to increased body mass index 
(BMI) in childhood, with sustained elevated BMI from age 1 year to 6 years
No difference was seen in fat percentage, but a proportional increase in lean 
mass, bone mass, and fat mass was seen at 6 years
These findings confirm that n-3 LCPUFA affects fetal programming leading to 
changed growth
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concluded that no evidence exists for n-3 LCPUFA 
supplementation affecting body mass index (BMI) or 
growth development in childhood.14-16 However, the 
amount of n-3 LCPUFA supplied varies widely, as does 
the combination of fatty acids used in the trials.
We had the opportunity to examine the question in 
the population based mother-child cohort Copenhagen 
Prospective Studies on Asthma in Childhood2010 
(COPSAC2010), in which we did a double blind, 
randomised controlled trail of n-3 LCPUFA (fish oil) 
versus control (olive oil) supplementation from week 
24 of pregnancy to one week postpartum.14 The 
primary endpoint of asthma or persistent wheeze 
showed a 31% reduction in risk in the group receiving 
fish oil.15 As a secondary endpoint, we aimed to 
investigate the effect of n-3 LCPUFA supplementation 
on growth and body composition in the offspring. We 
assessed BMI development at 11 clinical visits from 
birth to age 6 years and measured body composition 
from dual energy x ray absorptiometry scans at 3.5 and 
6 years of age.
Methods
Trial design
This was a single centre, double blind, placebo 
controlled, parallel group study of 736 mothers and 
their children.15 The recruitment procedure is detailed 
in the supplementary methods. The primary outcome 
of the n-3 LCPUFA trial was persistent wheeze/
asthma.14 15 As a pre-defined secondary endpoint, we 
investigated anthropometric measurements through 
childhood and body composition by dual energy x ray 
absorptiometry scans.15
Trial intervention
The women were randomised 1:1 in a double 
blind design at pregnancy week 24 to either 
daily supplementation of 2.4 g n-3 LCPUFA 
(55% eicosapentaenoic acid (20:5 n-3) and 37% 
docosahexaenoic acid (22:6 n-3), Incromega TG33/22, 
Croda Health Care, UK) in triacylglycerol form or 
lookalike control supplementation capsules of olive 
oil (72% n-9 oleic acid and 12% n-6 linoleic acid, 
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Pharmatech A/S, Norway). The supplementation was 
continued until one week after birth, and the trial 
was unblinded when the youngest child reached age 
3 years.
Maternal fatty acid desaturase genotype
Maternal fatty acid desaturase (FADS) gene variation 
was tagged by genotyping of the single nucleotide 
polymorphism rs1535 (LGC Limited, Hoddesdon, 
UK) in mothers of European descent (supplementary 
methods).15  16 We used the FADS genotype to do a 
genetic validation of our findings.
Adherence
We assessed adherence to the intervention by 
comparing the number of returned capsules against 
the expected number.
Anthropometry
Anthropometry was assessed at the COPSAC research 
unit at age 1 week, 1 month, 3 months, and 6 months, 
then every sixth month until age 2 years, and thereafter 
every year until age 6 years. The total number of visits 
to our clinic was 11.
Weight was measured without clothes by using 
calibrated digital weight scales. Length was measured 
until age 2 years by using an infantometer (Kiddimeter; 
Raven Equipment Ltd, Dunmow, Essex, England). 
Height from age 2 years and parental height were 
measured with a stadiometer (Harpenden, Holtain Ltd, 
Crymych, Dyfed, Wales), which was calibrated yearly.
Head circumference was measured with a tape, 
using the largest diameter as the endpoint. Waist 
circumference was measured with a tape, using the 
navel as a fix point; we used the mean of two measures 
during inspiration and expiration. We calculated 
World Health Organization age and sex specific BMI z 
scores for all measurements from 1 week to 6 years of 
age.16 We used International Obesity Task Force (IOTF) 
cut-offs for BMI to determine risk of overweight and 
obesity (above grade zero) and underweight (below 
grade zero).17
We obtained birth length and weight at the first 
clinical visit after birth by personal interview and 
validated the values against data from the Danish 
National Birth Registry. If the difference was larger 
than 10 g and 5 cm, we further validated data against 
the length and weight measures at 1 week from the 
research clinic. We derived size for gestational age 
from Marsál’s ultrasound based intrauterine growth 
curves.18 We used this standardized fetal growth curve 
to find the difference between each child’s birth weight 
and the expected birth weight given the gestational age 
and then calculated the percentage of expected birth 
weight. Percentage for gestational age is a sensitive 
measure for all ages.
Dual energy x ray absorptiometry scans
We did whole body scans with a Lunar iDXA 
densitometer (GE Healthcare, Fairfield, CT, USA) at 
3.5 and 6 years of age. We analysed data on fat mass, 
lean mass (total mass minus bone mineral content and 
fat mass), bone mineral content, and bone mineral 
density for the total body less head.19 In addition, for 
fat mass and lean mass, we analysed specific regions 
of interest.20-22 We also calculated the percentage of fat 
mass and lean mass for total body mass less head and 
regions of interest. All analyses on dual energy x ray 
absorptiometry scan data were adjusted for sex and 
age at measurement. All analyses on body composition 
from the scans were adjusted for height+height2 with 
regards to fat mass and lean mass and adjusted for 
height with regards to bone mineral content and bone 
mineral density. All dual energy x ray absorptiometry 
scan data were validated by an experienced specialist 
and analysed with enCore software.
Baseline characteristics
Collection and definition of baseline characteristics of 
the participants are described in the supplementary 
methods.
Statistical analysis
We included children with at least one anthropometric 
measurement at age 0-6 years and excluded twin 
pregnancies. We analysed the effect of n-3 LCPUFA 
supplementation on cross sectional anthropometric 
outcomes at 6 years of age (defined as the specific 
anthropometric measurement closest to 6 years±6 
months) by using Student’s t test for normally 
distributed continuous variables and χ2 tests for 
categorical variables.
We analysed changes in BMI over time in a random 
intercept mixed model with BMI z scores as the 
outcome. Age related trends in the association between 
intervention and BMI were investigated in the mixed 
models by inclusion of an interaction term between 
age and intervention group. We treated missing 
observations as missing data and excluded them from 
analyses. The analyses were done for all children and 
stratified by sex. We found no interaction between the 
intervention with n-3 LCPUFA and an intervention 
with high dose vitamin D (data not shown).
We used R v3.1.0 (R Foundation for Statistical 
Computing, Vienna, Austria) for all data analyses 
and considered results with a P value below 0.05 
to be statistically significant. The trial was powered 
according to the primary outcome of persistent wheeze/
asthma. Therefore, the power of the randomised 
controlled trial on BMI was calculated post hoc on 
the basis of the 605 children who had six year BMI 
data available. This resulted in 80% power to detect a 
mean difference of 0.19 in BMI z score, with a standard 
deviation of 0.82. The power/sample size calculation 
and testing were based on a two sample, two tailed t 
test with an α of 0.05.
We analysed for interaction with regards to sex, age, 
size for gestational age, fatty acid desaturase genotype, 
and maternal pre-intervention blood concentrations 
of eicosapentaenoic acid and docosahexaenoic 
acid. A subgroup from this pregnancy cohort also 
participated in a nested, factorial designed, double 
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blind, randomised controlled trial of 2400 IU/day of 
vitamin D3 supplementation (n=576). We did a sub-
analysis excluding children with asthma at age 6 years 
and/or with lower respiratory tract infections before 
age 3 years. In a sub-analysis, we adjusted our primary 
outcomes for size for gestational age and birth weight.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. We 
will disseminate the results of the research to study 
participants and the general public.
Results
Baseline characteristics
Enrolment ran from November 2008 to November 
2010. We randomised 736 women at pregnancy week 
24 to either n-3 LCPUFA or control supplementation 
(supplementary figure A); after excluding twin 
pregnancies, we included 688 children with at least 
one available anthropometric measurement in the trial, 
341 (49%) in the n-3 LCPUFA supplementation group 
and 347 (51%) in the control group. Of these children, 
605 (88%) had anthropometric measurements at the 
6 years visit. Table 1 shows baseline characteristics 
of the pregnant women and their children, indicating 
successful randomisation.
Adherence
We estimated adherence to the study supplementation, 
defined as an intake of more than 80% of the prescribed 
dose based on capsule count, to be 71%. We found 
no differences between the n-3 LCPUFA (n=242) and 
control group (n=245).
n-3 LCPUFA supplementation and BMI development 
during childhood
The n-3 LCPUFA supplementation group had a 
significantly higher BMI z score from 1 week to 
6 years of age compared with the control group, 
estimated using a mixed effects model of the repeated 
measurements of BMI (mean z score difference 0.14 
(95% confidence interval 0.04 to 0.23); P=0.006). We 
observed a significant interaction between age and 
intervention group (P for interaction=0.03). Figure 1 
(top) illustrates development of BMI from birth to age 
6 years according to intervention group, showing that 
children in the n-3 LCPUFA group had a higher BMI at 
age 1 week and a higher BMI from 1 year to 6 years, 
whereas no clear separation in BMI z score existed in 
the age range 1 week to 6 months (fig 1, bottom).
Table 1 | Baseline characteristics of COPSAC2010 mother-child pairs who participated in n-3 long chain polyunsaturated 
fatty acids (n-3 LCPUFA) randomised controlled trial. Values are percentages (numbers) unless stated otherwise
Characteristics All (n=688) n-3 LCPUFA (n=341; 49%) Control (n=347; 51%)
Children
Male sex 51 (351) 49 (166) 53 (185)
White ethnicity 96 (660) 97 (330) 95 (330)
Season of birth:
 Winter 31 (210) 28 (96) 33 (114)
 Spring 27 (184) 28 (94) 26 (90)
 Summer 21 (147) 21 (73) 21 (74)
 Autumn 21 (147) 23 (78) 20 (69)
Mean (SD) exclusive breast feeding, days 103 (60) 104 (59) 103 (60)
Mean (SD) difference in Marsál percentage* 49.6 (28.4) 51.5 (28.4) 47.8 (28.3)
Born before week 37 4 (26) 4 (12) 4 (14)
Mean (SD) age at 6 years BMI measurement, years 6.0 (0.2) 6.0 (0.2) 6.0 (0.2)
Mean (SD) age at 6 years DXA scanning, years 6.2 (0.2) 6.2 (0.2) 6.2 (0.2)
Parents
Mean (SD) maternal age at birth, years 32.2 (4.5) 32.3 (4.4) 32.1 (4.5)
Mean (SD) social circumstances† 0.0 (1.0) 0.0 (1.0) 0.0 (1.0)
Mean (SD) maternal pre-pregnancy BMI 24.6 (4.4) 24.7 (4.2) 24.4 (4.6)
Maternal asthma‡ 26 (181) 25 (84) 28 (97)
Mean (SD) paternal height, cm 181 (6.7) 181 (6.3) 181 (7.1)
Mean (SD) daily fish intake before inclusion, g 28 (18) 28 (17) 28 (18)
Mean (SD) maternal pre-treatment blood concentrations of EPA+DHA§, % 4.9 (1.2) 4.9 (1.3) 4.9 (1.2)
Pregnancy
Primiparity 46 (314) 44 (151) 47 (163)
Pre-eclampsia 4 (30) 4 (15) 4 (15)
Smoking in pregnancy 8 (52) 6 (20) 9 (32)
Antibiotics in pregnancy 35 (239) 35 (119) 35 (120)
Mean (SD) Hadlock calculated in utero weight, g 322.9 (53.4) 320.7 (49.2) 325.2 (57.2)
High dose vitamin D intervention 42 (291) 41 (141) 43 (150)
BMI=body mass index; DHA=docosahexaenoic acid; DXA=dual energy x ray absorptiometry; EPA=eicosapentaenoic acid.
*Calculation was based on Marsál’s intrauterine growth curves.
†Social circumstances in household defined as first component of principal component analysis on household income, maternal age, and maternal level of 
education (see supplementary methods).
‡History of asthma diagnosed by doctor.
§Relative percentage of measured blood fatty acids.
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A sensitivity analysis restricted to children with all 
11 growth measurements (n=414) showed similar 
results (mean z score difference 0.18 (0.06 to 0.31); 
P=0.004). The effects of the intervention on BMI 
z score development was similar in boys and girls 
(supplementary figure B), and no significant interaction 
existed between sex and intervention group (P=0.79).
Because n-3 LCPUFA supplementation also 
reduced the risk of asthma and lower respiratory tract 
infections,15 we did a sub-analysis excluding children 
with asthma at age 6 years, lower respiratory tract 
infections before age 3 years, or both. This did not affect 
the association between n-3 LCPUFA supplementation 
and BMI development (data not shown).
n-3 LCPUFA supplementation and anthropometric 
measurements at 6 years of age
Children in the n-3 LCPUFA supplementation group 
had a significantly higher BMI z score at age 6 years 
compared with the control group (sex and age adjusted: 
mean difference 0.19 (0.06 to 0.32); P=0.004), a higher 
weight/height (3.48 (0.38 to 6.57) g/cm; P=0.03), 
and a larger waist circumference (0.6 (0.0 to 1.2) cm; 
P=0.04), whereas no differences existed in height or 
head circumference (table 2).
A higher proportion of children from the n-3 LCPUFA 
supplementation group had a BMI z score in the highest 
quarter (29% (n=91) v 21% (n=62); P=0.02) and fewer 
had a z score in the lowest quarter (21% (n=66) v 30% 
(n=90); P=0.02) compared with the control group. 
However, no significant differences existed between the 
intervention groups among children with the highest 
or lowest 10% of BMI z score or in the prevalence of 
overweight or underweight children according to 
IOTF grades (table 2). Sex stratified analysis yielded 
no difference (supplementary table  A). Adjusting the 
analyses for size for gestational age yielded comparable 
results (data not shown).
We found no interaction between the intervention 
and sex, size for gestational age, or maternal pre-
intervention blood concentrations of eicosapentaenoic 
acid and docosahexaenoic acid in relation to 
the anthropometric outcomes (data not shown). 
Furthermore, no interaction existed between the 
intervention with n-3 LCPUFA and the intervention 
with high dose vitamin D (data not shown).
We did a sub-analysis on the primary anthropometric 
outcomes in which we adjusted the analyses for size for 
gestational age; this yielded comparable results (data 
not shown). Furthermore, we adjusted the primary 
anthropometric outcomes for birth weight, and this 
also yielded comparable significant results, although 
with a small reduction in the effect of n-3 LCPUFA 
supplementation (data not shown).
n-3 LCPUFA supplementation and body composition
At 6 years of age, 523 (76%) of 688 children completed 
a dual energy x ray absorptiometry scan. The n-3 
LCPUFA group had a higher total body mass in the 
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Fig 1 | Top: curves showing mean body mass index (BMI) 
according to visit age for children in n-3 long chain 
polyunsaturated fatty acid (n-3 LCPUFA) supplementation 
group and control group up to age 6 years. Bottom: 
effects of n-3 LCPUFA supplementation on BMI through 
infancy and childhood, illustrated by mean difference in 
BMI z score at each visit and 95% confidence intervals
Table 2 | Effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) on anthropometric measurements at 6 years 
of age
Measurement n-3 LCPUFA (n=304) Control (n=301) P value
Mean (SD) BMI z score 0.1 (0.8) −0.1 (0.8) 0.004
Mean (SD) waist circumference, cm 55.5 (3.8) 54.8 (3.7) 0.04
Mean (SD) weight, kg 21.8 (2.9) 21.4 (2.9) 0.11
Mean (SD) height, cm 118.2 (4.6) 118.2 (5.1) 0.97
Mean (SD) weight/height, g/cm 183.7 (19.1) 180.7 (18.7) 0.03
Mean (SD) head circumference, cm 52.1 (1.4) 52.1 (1.4) 0.83
% BMI z score <10/>90th centile 9/11 11/10 0.63
% (No) BMI z score <25th centile 22 (66) 30 (90) 0.02
% (No) BMI z score >75th centile 30 (91) 21 (62) 0.02
% (No) IOTF grade>0* 5 (16) 5 (14) 0.89
% (No) IOTF grade<0† 9 (26) 10 (30) 0.62
BMI=body mass index; IOTF=International Obesity Task Force.
*IOTF above grade zero means child is at risk of adulthood overweight and obesity.
†IOTF below grade zero means child is at risk of adulthood underweight.
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total body less head compartment compared with 
controls (19 361.0 v 18 967.0 g; height adjusted mean 
difference 395.4 (86.6 to 704.3) g; P=0.01). This was 
similar to the measured weight difference at age 6 
years.
Sub-analyses on tissue type showed that the 
children in the n-3 LCPUFA supplementation group 
had a significantly higher lean mass in the total body 
less head compartment (mean difference 280.7 (98.9 
to 462.4) g; P=0.002) and in the trunk (127.2 (29.4 
to 242.9) g; P=0.01). Children in the n-3 LCPUFA 
supplementation group had a higher total body less 
head bone mineral content (10.3 (2.3 to 18.1) g; 
P=0.01) and a trend towards a higher bone mineral 
density (0.005 (−0.001 to 0.012) g/cm2; P=0.08). 
The n-3 LCPUFA supplementation group had a non-
significantly higher fat mass in total body less head 
(116.3 (−92.9 to 325.5) g; P=0.28), but we found no 
difference in total body fat percentage or lean mass 
percentage (table 3). Figure 2 shows the proportional 
increase in lean, fat, and bone mass for children in the 
n-3 LCPUFA supplementation group at 6 years of age.
At 3.5 years of age, 356 (52%) of 688 children had 
available dual energy x ray absorptiometry scan data. 
No significant differences in body composition existed 
between the groups, but all estimates for lean mass, 
fat mass, and bone mineral content were higher in 
the n-3 LCPUFA supplementation group than the 
control group (supplementary table B). The number of 
participants completing the scans at 3.5 and 6 years 
was equal in the two supplementation groups (176 v 
180 at 3.5 years; 263 v 260 at 6 years).
No interaction existed between the intervention 
and sex, size for gestational age, or maternal pre-
intervention blood concentrations of eicosapentaenoic 
acid and docosahexaenoic acid in relation to the body 
composition outcomes at 6 years (data not shown).
Maternal FADS genotype and BMI development 
during childhood
In a sub-analysis, we investigated whether maternal 
FADS genotype was associated with BMI z score 
development and body composition of offspring. 
The maternal FADS gene variant rs1535 has 
been associated with blood concentrations of 
eicosapentaenoic acid and docosahexaenoic acid 
during pregnancy.23  24 We stratified the data by 
intervention groups and investigated the difference in 
BMI z score between children born to mothers with the 
FADS genotypes associated with higher concentrations 
of eicosapentaenoic acid and docosahexaenoic acid 
(AA/AG) and those with the genotype associated with 
lower concentrations (GG). In the control group, we 
found that the children born to mothers with the AA/
AG genotype tended to have higher BMI z score values 
from 1 to 6 years of age (mean difference 0.2 (−0.0 to 
0.5); P=0.08) and higher BMI z score at 6 years of age 
(mean difference 0.3 (0.1 to 0.5); P=0.01) compared 
with children born to mothers with the GG genotype 
(supplementary figure C and table C). In contrast, we 
found no association between FADS genotype and 
BMI z score or other anthropometrics outcomes in 
the n-3 LCPUFA supplemented group. No significant 
interactions existed between FADS genotype and effect 
from the intervention in relation to BMI z score or other 
anthropometric outcomes (table 3).
Discussion
Supplementation with n-3 LCPUFA in the third 
trimester of pregnancy resulted in a higher BMI in the 
children from age 1 to 6 years but no increase in the 
number of obese children. Body composition assessed 
by dual energy x ray absorptiometry scans confirmed 
that the higher BMI was not the result of a higher fat 
percentage but reflected a proportional increase in 
lean mass, bone mass, and fat mass, suggesting a 
general growth stimulating effect of the n-3 LCPUFA 
supplementation.
Strengths and limitations of study
Our trial is among the largest randomised controlled 
trials on n-3 LCPUFA supplementation in pregnancy. 
It is nested in a population based cohort, increasing 
Table 3 | Effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) on dual energy x ray absorptiometry 
measurements at 6 years of age. Values are mean (SD) unless stated otherwise
Measurement
Crude Adjusted*
n-3 LCPUFA (n=263) Control (n=260) Estimate (95% CI) P value
Fat (TBLH), kg 4.78 (1.56) 4.64 (1.40) 0.12* (−0.09 to 0.33) 0.28
Fat % (TBLH) 24.4 (5.0) 24.2 (4.9) 0.1 (−0.7 to 0.8) 0.83
Fat (trunk), kg† 1.80 (0.73) 1.76 (0.68) 0.02 (−0.08 to 0.13) 0.69
Fat % (trunk) 18.1 (5.2) 18.0 (5.2) 0.2 (−0.6 to 1.0) 0.83
Fat (android), kg† 0.21 (0.11) 0.20 (0.11) 0.003 (−0.01 to 0.02) 0.71
Fat % (android) 15.1 (5.7) 14.9 (5.8) 0.1 (−0.8 to 1.0) 0.79
Lean mass (TBLH), kg† 14.0 (2.02) 13.8 (2.08) 0.28 (0.10 to 0.46) 0.02
Lean mass % (TBLH) 72.8 (4.9) 73.0 (4.8) 0.0 (−0.7 to 0.7) 0.94
Lean mass (trunk), kg† 7.75 (1.03) 7.65 (1.06) 0.15 (0.03 to 0.22) 0.01
Lean mass % (trunk) 79.6 (5.2) 79.7 (5.2) −0.1 (−0.9 to 0.7) 0.76
Total BMC (TBLH), kg‡ 0.55 (0.09) 0.54 (0.09) 0.01 (0.002 to 0.02) 0.01
Total BMD (TBLH), g/cm2‡ 0.56 (0.05) 0.56 (0.05) 0.005 (−0.006 to 0.01) 0.08
BMC=bone mineral content; BMD=bone mineral density; TBLH=total body less head.
*Adjusted for age and sex.
†Additionally adjusted for height and height2.
‡Additionally adjusted for height.
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the external validity of our findings. Adherence to 
both the supplementations (71%) and the trial was 
high, with 88% of the children having anthropometric 
measurements at age 6 years.
The longitudinal clinical follow-up with 11 visits 
during the first six years of life, including a broad range 
of anthropometric measures, is a significant strength 
of the trial. Each growth measurement was made using 
the same equipment by trained COPSAC assistants 
on the basis of standard operating procedures, and 
the observed growth curves were similar to previous 
reports.20
Another strength is the dual energy x ray 
absorptiometry scans providing objective measures of 
fat mass, lean mass, and bone mass, which enabled 
us to disentangle which tissues were affected by the 
intervention. The dual energy x ray absorptiometry 
estimates showed the same tendency at 3.5 years as at 
6 years.
The observation of a higher BMI and higher weight 
in children born to mothers with the FADS genotypes 
causing higher concentrations of eicosapentaenoic 
acid and docosahexaenoic acid in the control group 
provides indirect support for our findings from the 
n-3 LCPUFA intervention, as this genetic variation is a 
marker not confounded by maternal eicosapentaenoic 
acid and docosahexaenoic acid intake.
The main limitation of the study is the follow-up 
to only 6 years of age, but the cohort is still being 
followed. Furthermore, we are reporting results on 
a secondary outcome. The power calculation was 
performed on our primary outcome: persistent wheeze 
or asthma. Therefore, we did not have the statistical 
power to examine the risk of developing either 
underweight or overweight according to IOTF grades. 
This makes interpretation of potential long term 
clinical implications difficult.
Interpretation
This trial is the first to show that n-3 LCPUFA 
supplementation in the third trimester of pregnancy 
leads to a higher BMI in offspring through childhood, 
whereas previous trials and systematic reviews 
showed no effect of n-3 LCPUFA supplementation 
during pregnancy and/or lactation on BMI or 
growth development in childhood.7  8  9  21  22 Potential 
explanations for the discrepancy between our findings 
and previous studies include differences in the 
dose and type of n-3 LCPUFA supplied, the timing 
of the supplementation, the trial design, and the 
accuracy of measurements. The dose of n-3 LCPUFA 
in our trial was 2.4 g per day, which is higher than 
in most previous studies, in which 900 mg or 1.5 
g was administered,7  9  25  26 and the high number of 
participants increased the statistical power to detect 
effects on growth and body composition compared 
with previous studies.27 One other trial supplemented 
with a dose similar to ours from week 30 of pregnancy 
and completed follow-up for 243 participants at age 
19 years, finding no effect on waist circumference or 
BMI, which could be caused by low numbers.28 In line 
with our findings, one previous trial supplementing 
mothers with 1.5 g n-3 LCPUFA (40% eicosapentaenoic 
acid) during the first four months of lactation showed 
a significantly higher BMI and increased waist 
circumference in the n-3 LCPUFA supplemented 
children at 2.5 years,29 but no differences were seen 
at 7 or 13 years of age.8 We previously reported that 
persistent wheeze/asthma in the first years of life 
was reduced by approximately one third in the n-3 
LCPUFA supplemented group.15 We could therefore 
speculate that the higher BMI through childhood might 
be mediated by an effect on asthma/airway diseases. 
However, we did not find any changes in the effect 
when we excluded children with asthma and/or lower 
respiratory tract infections.
The BMI development curves and the significant 
interaction with age suggest that the effect of n-3 
LCPUFA supplementation on BMI was most prominent 
after age 1 year. Risk of later obesity has been associated 
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Fig 2 | Density plot showing lean mass, bone mass, 
and fat mass stratified by supplementation groups: 
n-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) 
and control. Lean mass and fat mass are adjusted for 
(height+height2); g/cm+cm2. Bone mass is adjusted  
for height; g/cm.
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with early onset of peak BMI in infancy,30 which 
usually occurs at age 6 months. The lack of an effect 
of n-3 LCPUFA in the first year of life in our trial could 
therefore reflect that n-3 LCPUFA supplementation has 
a general growth stimulating effect, which does not 
increase the risk of overweight or obesity.
We have previously reported that n-3 LCPUFA 
supplementation resulted in a prolongation of 
pregnancy duration by two days, a higher birth weight, 
and increased size for gestational age (manuscript 
in review). However, adjusting the main analysis for 
size for gestational age did not change the results, so 
the increased BMI through childhood does not seem 
to be driven by the increased intrauterine growth. 
Furthermore, we did not find any differences between 
boys and girls, which is in line with most other 
studies.21
The n-3 LCPUFA supplementation in pregnancy 
led to a 0.4 kg higher weight at age 6 years, but our 
dual energy x ray absorptiometry data obtained at 3.5 
and 6 years showed no difference in bone mass, fat 
mass, or lean mass percentages. Instead, we observed 
a proportional increase in all three compartments 
in the children from the n-3 LCPUFA supplemented 
group. Furthermore, we did not find any differences 
between the intervention groups with regard to IOTF 
grades or children in the highest or lowest 10% of BMI 
at 6 years. This suggests that mainly children with a 
BMI in the normal range were affected by the n-3 
LCPUFA intervention. Also, the effect of n-3 LCPUFA 
supplementation on bone mineral content and bone 
mineral density might imply a positive health benefit 
in terms of decreased risk of later fragile bones.31
Finally, we interpret the effect on BMI z score 
through childhood as a consequence of a healthy 
somatic growth stimulation to age 6. The cohort will be 
followed into adulthood to evaluate whether the effects 
on growth and body composition induced by n-3 
LCPUFA supplementation in pregnancy are sustained.
Conclusion
Supplementation with n-3 LCPUFA in pregnancy led 
to a 0.4 kg higher weight in the first six years of life 
but not an increased risk of overweight or obesity. 
The n-3 LCPUFA supplementation resulted in a 
proportional increase in lean mass, bone mass, and fat 
mass, suggesting that n-3 LCPUFA supplementation 
in the third trimester of pregnancy stimulates healthy 
somatic growth to age 6 years.
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